Amylyx ended Q2 with $251 million in cash and marketable securities, enough to support operations into 2028. Costs rose as it prepared for Avexitide, and the trial results are still unknown, so the update does not change the company's outlook.
The cash reserve gives Amylyx time to keep working on Avexitide. But the main trial results are still unknown, and costs rose as the company prepared to sell the drug if approved. Those facts point in different directions, so this update does not change how we read Amylyx.
Follow Amylyx Pharma (AMLX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMLX